Pioglitazone

Drugs

Volumn 60, Issue 2, 2000, Pages 333-343

  Gillies, P S ^a   Dunn, C J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ARGIPRESSIN; BASIC FIBROBLAST GROWTH FACTOR; BROXURIDINE; DIGOXIN; ESTRONE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; GLUCOSE TRANSPORTER; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; LIPID; METFORMIN; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENPROCOUMON; PIOGLITAZONE; POTASSIUM CHLORIDE; SULFONYLUREA; U 72107E; VOGLIBOSE; WARFARIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES CONTROL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; GLUCOSE METABOLISM; HEADACHE; HUMAN; HYPOGLYCEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033851704     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060020-00009     Document Type: Review

References (56)

1. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
2. Insulin resistance syndrome: Options for treatment
3. An antidiabetic thiazoledinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ)
4. Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes
5. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells
6. A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs
7. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
8. Pioglitazone (Pio) augments early steps in the insulin transduction system
9. Antidiabetic agent pioglitazone increases insulin receptors on 3T3-L1 adipocytes
10. Altered expression of insulin signaling mediators in an animal model of NIDDM is partially corrected by pioglitazone (Pio) treatment
11. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
12. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase
13. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
14. Reduced expression of hexokinase II in insulin-resistant diabetes
15. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner
16. Effects of pioglitazone on white adipose tissue remodeling in obese fa/fa Zucker rats
17. Insulin sensitization in diabetic rat liver by an antihyperglycemic agent
18. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats
19. Insulin action on protein phosphatase-1 activation is enhanced by the antidiabetic agent pioglitazone in cultured diabetic hepatocytes
20. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats
21. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats
22. Effect of thiazolidinedione insulin sensitizer on growth and body composition of Zucker rats
23. Pioglitazone hydrochloride enhances hepatic insulin responsiveness in insulin-resistant KKA(Y) mice and streptozotocin diabetic rats
24. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys
25. Effect of pioglitazone in combination with metformin on diabetes and obesity in Wistar fatty rats
26. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
27. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus
28. Pioglitazone attenuates diet-induced hypertension in rats
29. Pioglitazone attenuates basal and postprandial insulin concentrations and decreases blood pressure in spontaneously hypertensive rats
30. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats
31. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect
32. Insulin sensitizing agent pioglitazone has antihypertensive and reno-/vasculo-protective effects in genetically obese-diabetic rats
33. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro
34. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization
35. Vasculo-protective effects of insulin-sensitizing agent pioglitazone in neointimal thickening and chronic hypertension
36. Effect of pioglitazone on atherosclerosis
37. Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth
38. The pharmacokinetics of AD-4833 in elderly subjects
39. Pioglitazone has low potential for drug interactions
40. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
41. Pharmacokinetics of pioglitazone in patients with renal impairment
42. Concomitant use of AD-4833, an insulin-resistance improver, and sulfonylureas: Effects on serum concentrations of sulfonylureas
43. Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy pharmacokinetics
44. The effects of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
45. Pioglitazone is effective in the treatment of patients with type 2 diabetes
46. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin-dependent diabetes mellitus (NIDDM) on diet therapy alone - A placebo-controlled double-blind clinical study
47. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
48. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
49. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
50. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
51. Adding pioglitazone to metformin therapy improves the lipid profile in patients with type 2 diabetes
52. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes
53. Clinical evaluation of an insulin sensitivity enhancer, AD-4833, in combination with voglibose in patients with noninsulin-dependent diabetes mellitus - A non-blind phase III study